Effects of antiresorptive agents on osteomyelitis: Novel insights into the pathogenesis of osteonecrosis of the jaw

Annals of the New York Academy of Sciences

Volumn 1192, Issue , 2010, Pages 84-94

  Li, Dan ^a   Gromov, Kirill ^a,b   Proulx, Steven T ^a   Xie, Chao ^a   Li, Jie ^a   Crane, Daniel P ^a   Søballe, Kjeld ^b   O'Keefe, Regis J ^a   Awad, Hani A ^a,c   Xing, Lianping ^a   Schwarz, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c University of Rochester   (United States)

Author keywords

Antiresorptive therapy; Osteomyelitis; TNFR:Fc

Indexed keywords

ALENDRONIC ACID; ETANERCEPT; GENTAMICIN; OSTEOPROTEGERIN; PLACEBO;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; BIOFILM; BONE MARROW; BONE NECROSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; GRAM POSITIVE BACTERIUM; GRANULOMA; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JAW OSTEONECROSIS; LYMPHATIC DRAINAGE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOMYELITIS; PATHOGENESIS;

BACTERIA (MICROORGANISMS); MUS;

EID: 77950658125     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05210.x     Document Type: Conference Paper

References (40)

1. Lew, D.P. & F.A. Waldvogel. 2004. Osteomyelitis. Lancet 364: 369-379. (Pubitemid 38976521)
2. Toms, A.D. et al. 2006. The management of periprosthetic infection in total joint arthroplasty. J. Bone Joint Surg. Br. 88: 149-155. (Pubitemid 43279921)
3. Darouiche, R.O. 2004.Treatment of infections associated with surgical implants. N. Engl. J. Med. 350: 1422-1429. (Pubitemid 38419996)
4. Klevens, R.M. et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771. (Pubitemid 47598444)
5. Wright, S.A. et al. 2005. Chronic diffuse sclerosing osteomyelitis treated with risedronate. J. Rheumatol. 32: 1376-1378. (Pubitemid 40995401)
6. Soubrier, M. et al. 2001. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 92: 637-640. (Pubitemid 33601778)
7. Marx, R.E. 2003. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61: 1115-1117.
8. Hellstein, J.W. & C.L. Marek. 2005. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J. Oral Maxillofac. Surg. 63: 682-689.
9. Shane, E. et al. 2006. Osteonecrosis of the jaw: more research needed. J. Bone Miner. Res. 21: 1503-1505. (Pubitemid 44484594)
10. Khosla, S. et al. 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone andMineralResearch. J. Bone Miner. Res. 22: 1479-1491. (Pubitemid 351229318)
11. Hewitt, C. & C.S. Farah. 2007. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J. Oral Pathol. Med. 36: 319-328. (Pubitemid 46889876)
12. Van Den Wyngaert, T. et al. 2007. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr. Opin. Oncol. 19: 315-322. (Pubitemid 46883519)
13. Gutta, R. & P.J. Louis. 2007. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg. OralMed. Oral Pathol.Oral Radiol. Endod. 104: 186-193.
14. Marx, R.E. et al. 2005. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63: 1567-1575.
15. Ruggiero, S.L. et al. 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62: 527-534.
16. Allegra, A. et al. 2007. Patients with bisphosphonatesassociated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol. Oncol. 25: 164-169.
17. Bagan, J.V. et al. 2005. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J. Oral Pathol. Med. 34: 120-123.
18. Hansen, T. et al. 2006. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J. Oral Pathol. Med. 35: 155-160.
19. Li, D. et al. 2008. Quantitative mousemodel of implantassociated osteomyelitis and the kinetics of microbial growth, osteolysis, and humoral immunity. J. Orthop. Res. 26: 96-105.
20. Francis, K.P. et al. 2000. Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct. Infect. Immun. 68: 3594-3600.
21. Rodan, G.A.& T.J.Martin. 2000. Therapeutic approaches to bone diseases. Science 289: 1508-1514.
22. Teitelbaum, S.L. 2007. Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170: 427-435.
23. Zhang, X. et al. 2005. Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. J. Bone Miner. Res. 20: 2124-2137. (Pubitemid 41698776)
24. Hildebrand, T. et al. 1999. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data fromspine, femur, iliac crest, and calcaneus. J. Bone Miner. Res. 14: 1167-1174. (Pubitemid 29314060)
25. Proulx, S.T. et al. 2007. Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum. 56: 4024-4037.
26. Proulx, S.T. et al. 2007. MRI and quantification of draining lymph node function in inflammatory arthritis. Ann. N. Y. Acad. Sci. 1117: 106-123.
27. Ito, H. et al. 2005. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat. Med. 11: 291-297. (Pubitemid 40460557)
28. Gortz, B. et al. 2004. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J. Bone Miner. Res. 19: 990-998. (Pubitemid 41103456)
29. Schwarz, E.M. et al. 2000. A quantitative small animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J. Ortho. Res. 18: 849-855.
30. Li, P. et al. 2004. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 50: 265-276. (Pubitemid 38084312)
31. Flynn, J.L. et al. 1995. Tumor necrosis factor-alpha is required in the protective immune response againstMycobacterium tuberculosis in mice. Immunity 2: 561-572.
32. Dougall,W.C. et al. 1999.RANKis essential for osteoclast and lymph node development. Genes Dev. 13: 2412-2424.
33. Kong, Y.Y. et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 397: 315-323. (Pubitemid 29061638)
34. Anderson, D.M. et al. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
35. Bachmann, M.F. et al. 1997. TRANCE, a tumor necrosis factor family member critical for CD40 ligandindependent T helper cell activation. J. Exp. Med. 189: 1025-1031.
36. Stolina, M. et al. 2003. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin. Immunol. 109: 347-354. (Pubitemid 38091454)
37. Sobacchi, C. et al. 2007. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39: 960-962. (Pubitemid 47185178)
38. Schwarz, E.M. & C.T. Ritchlin. 2007. Clinical development of anti-RANKL therapy. Arthritis Res. Ther. 29: 1-7.
39. Zhang, Q. et al. 2008. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J. Biol. Chem. 283: 13491-13499.
40. Hamner, J.B. & M.D. Fleming. 2007. Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer. Ann. Surg. Oncol. 14: 1904-1908.